Ipamorelin
← All compounds

Ipamorelin

Well Researched

First effectsWeek 1-2
Full benefitsWeek 8-12
Regulatory Limbo

Ipamorelin is a selective peptide that tells your pituitary gland to release more growth hormone. It has a clean side-effect profile with minimal impact on cortisol and prolactin levels, making it well suited for body composition, recovery, and anti-aging applications.

How it works

Ipamorelin injection provides direct systemic delivery for consistent growth hormone pulses. It works by binding to ghrelin receptors in the pituitary gland, triggering natural growth hormone release without raising cortisol, prolactin, or causing significant hunger.

Key benefits

  • Stimulates natural growth hormone release with a clean side-effect profile
  • Improves body composition by supporting lean mass and fat loss
  • Enhances recovery from exercise and physical stress
  • Promotes deeper sleep and better morning energy
  • Supports skin quality and anti-aging benefits over time

Related goals

Protocols

ProtocolDoseFrequency
General Health & Longevity200mcg1x daily before bed
Body Composition250-300mcg2x daily (morning, pre-workout)
Athletic Performance200-250mcg2-3x daily (morning, pre/post workout)
Sleep & Recovery200mcg1x daily 30min before bed
Anti-Aging Protocol200-250mcg1-2x daily (morning, bedtime)

Protocols are from published research literature. This is not medical advice. Dosing should be determined by a licensed clinician.

What to expect

Week 1-2

Improved sleep quality, deeper sleep, better morning energy

Week 2-4

Enhanced recovery from exercise, reduced muscle soreness

Week 4-8

Body composition improvements, increased lean mass, fat loss

Week 8-12

Continued improvements in muscle tone, skin quality, energy

What to know

  • Use sterile injection technique to prevent infection
  • May cause mild hunger increase 20-30 minutes post-injection
  • Monitor for receptor desensitization after 3-4 months of continuous use
  • Cycle off periodically to maintain effectiveness and receptor sensitivity
  • Not recommended during pregnancy, breastfeeding, or active cancer

Key research

Raun K et al. · European Journal of Endocrinology · 1998
Sigalos JT et al. · Sexual Medicine Reviews · 2018
Svensson J et al. · Journal of Endocrinology · 2000
Andersen NB et al. · Growth Hormone & IGF Research · 2001